By Sabela OjeaOragenics said President Michael Redmond will act as interim principal executive officer after the company signed a separation agreement with Chief Executive Kimberly Murphy. The development-stage pharmaceutical company focused on nasal delivery of medications in neurology and infectious diseases on Monday said Murphy, who joined the board in 2020, will continue as a board director.

Source: Wall Street Journal February 12, 2024 23:29 UTC